Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTBWMKT)

• DTT Name: WWP1 messenger RNA (WWP1 mRNA)
• Synonyms: WW domain-containing protein 1 (mRNA); Tiul1 (mRNA); TGIF-interacting ubiquitin ligase 1 (mRNA); NEDD4-like E3 ubiquitin-protein ligase WWP1 (mRNA); HECT-type E3 ubiquitin transferase WWP1 (mRNA); Atrophin-1-interacting protein 5 (mRNA); AIP5 (mRNA)
• Gene Name: WWP1
• DTT Type: Literature-reported target; [1]
• BioChemical Class: mRNA target
• UniProt ID: WWP1_HUMAN
• TTD ID: T91154
• EC Number: EC 2.3.2.26
• Sequence:
  MATASPRSDTSNNHSGRLQLQVTVSSAKLKRKKNWFGTAIYTEVVVDGEITKTAKSSSSS
  NPKWDEQLTVNVTPQTTLEFQVWSHRTLKADALLGKATIDLKQALLIHNRKLERVKEQLK
  LSLENKNGIAQTGELTVVLDGLVIEQENITNCSSSPTIEIQENGDALHENGEPSARTTAR
  LAVEGTNGIDNHVPTSTLVQNSCCSYVVNGDNTPSSPSQVAARPKNTPAPKPLASEPADD
  TVNGESSSFAPTDNASVTGTPVVSEENALSPNCTSTTVEDPPVQEILTSSENNECIPSTS
  AELESEARSILEPDTSNSRSSSAFEAAKSRQPDGCMDPVRQQSGNANTETLPSGWEQRKD
  PHGRTYYVDHNTRTTTWERPQPLPPGWERRVDDRRRVYYVDHNTRTTTWQRPTMESVRNF
  EQWQSQRNQLQGAMQQFNQRYLYSASMLAAENDPYGPLPPGWEKRVDSTDRVYFVNHNTK
  TTQWEDPRTQGLQNEEPLPEGWEIRYTREGVRYFVDHNTRTTTFKDPRNGKSSVTKGGPQ
  IAYERGFRWKLAHFRYLCQSNALPSHVKINVSRQTLFEDSFQQIMALKPYDLRRRLYVIF
  RGEEGLDYGGLAREWFFLLSHEVLNPMYCLFEYAGKNNYCLQINPASTINPDHLSYFCFI
  GRFIAMALFHGKFIDTGFSLPFYKRMLSKKLTIKDLESIDTEFYNSLIWIRDNNIEECGL
  EMYFSVDMEILGKVTSHDLKLGGSNILVTEENKDEYIGLMTEWRFSRGVQEQTKAFLDGF
  NEVVPLQWLQYFDEKELEVMLCGMQEVDLADWQRNTVYRHYTRNSKQIIWFWQFVKETDN
  EVRMRLLQFVTGTCRLPLGGFAELMGSNGPQKFCIEKVGKDTWLPRSHTCFNRLDLPPYK
  SYEQLKEKLLFAIEETEGFGQE
• Function: Ubiquitinates ERBB4 isoforms JM-A CYT-1 and JM-B CYT-1, KLF2, KLF5 and TP63 and promotes their proteasomal degradation. Ubiquitinates RNF11 without targeting it for degradation. Ubiquitinates and promotes degradation of TGFBR1; the ubiquitination is enhanced by SMAD7. Ubiquitinates SMAD6 and SMAD7. Ubiquitinates and promotes degradation of SMAD2 in response to TGF-beta signaling, which requires interaction with TGIF. E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.
• KEGG Pathway:
  Ubiquitin mediated proteolysis (hsa04120)
  Endocytosis (hsa04144)
• Reactome Pathway:
  Antigen processing (R-HSA-983168)
  Stimuli-sensing channels (R-HSA-2672351)

Molecular Interaction Atlas (MIA) of This DTT

14 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 103582	DME9Q8L	Discovery agent	N.A.	Investigative	[1]
ISIS 103601	DM6BH7K	Discovery agent	N.A.	Investigative	[1]
ISIS 103612	DM298KT	Discovery agent	N.A.	Investigative	[1]
ISIS 103613	DMNPMW4	Discovery agent	N.A.	Investigative	[1]
ISIS 103615	DMGTX6O	Discovery agent	N.A.	Investigative	[1]
ISIS 103616	DM3PK2G	Discovery agent	N.A.	Investigative	[1]
ISIS 103619	DMERJAV	Discovery agent	N.A.	Investigative	[1]
ISIS 103620	DM61FYM	Discovery agent	N.A.	Investigative	[1]
ISIS 103621	DMP7VJL	Discovery agent	N.A.	Investigative	[1]
ISIS 103622	DM9J4I3	Discovery agent	N.A.	Investigative	[1]
ISIS 103624	DMST2QW	Discovery agent	N.A.	Investigative	[1]
ISIS 103629	DMJLHE7	Discovery agent	N.A.	Investigative	[1]
ISIS 103631	DMOK9FA	Discovery agent	N.A.	Investigative	[1]
ISIS 103635	DMVW7N5	Discovery agent	N.A.	Investigative	[1]

References

• [1] US patent application no. 6,258,601, Antisense modulation of ubiquitin protein ligase expression.